Difference between revisions of "Dambrova 2022 MitoFit"
Tindle Lisa (talk | contribs) (Created page with "{{MitoFit page name}} {{Publication |title=Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targ...") |
|||
| Line 1: | Line 1: | ||
[[File:Bioblast2022 banner.jpg|link=Bioblast_2022]] | |||
{{MitoFit page name}} | {{MitoFit page name}} | ||
{{Publication | {{Publication | ||
|title=Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. MitoFit Preprints 2022.20. https://doi.org/10.26124/mitofit:2022-0020 | |title=Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. MitoFit Preprints 2022.20. https://doi.org/10.26124/mitofit:2022-0020 | ||
|info=[[File:MitoFit Preprints pdf.png|left|160px|link=https://wiki.oroboros.at/images/d/d2/Dambrova_2022_Mitofit.pdf|MitoFit pdf]] [https://wiki.oroboros.at/images/d/d2/Dambrova_2022_Mitofit.pdf Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets]<br/> | |info=[[File:MitoFit Preprints pdf.png|left|160px|link=https://wiki.oroboros.at/images/d/d2/Dambrova_2022_Mitofit.pdf|MitoFit pdf]] [https://wiki.oroboros.at/images/d/d2/Dambrova_2022_Mitofit.pdf Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets]<br/> | ||
|authors=Dambrova Maija, Cecatto Cristiane, Vilskersts Reinis, Liepinsh Edgars | |authors=Dambrova Maija, Cecatto Cristiane, Vilskersts Reinis, Liepinsh Edgars | ||
|year=2022-05-20 | |year=2022-05-20 | ||
|journal=MitoFit Prep | |journal=MitoFit Prep | ||
|abstract= | |abstract=[[File:Dambrova 2022 graphical abstract.png|right|250px|Graphical abstract]] | ||
[[File:Dambrova 2022 graphical abstract.png|right|250px|Graphical abstract]] | |||
Acylcarnitines are esters of L-carnitine that emerge from the fatty acid metabolism pathways in mitochondria and peroxisomes. | Acylcarnitines are esters of L-carnitine that emerge from the fatty acid metabolism pathways in mitochondria and peroxisomes. | ||
Metabolomic profiling assays that investigate disease and nutrition states often include measurements of different acylcarnitines. This has resulted in increased interest regarding the consequences of increased/decreased levels of plasma acylcarnitine concentrations and the mechanisms associated with these changes. Altered acylcarnitine metabolome is characteristic of certain inborn errors of fatty acid metabolism, as well as cardiovascular, metabolic, and neurological diseases in addition to some forms of cancer. Long-chain acylcarnitines accumulate under conditions of insufficient mitochondrial functionality reaching tissue levels that can affect enzyme and ion channel activities, and impact energy metabolism pathways and cellular homeostasis. | Metabolomic profiling assays that investigate disease and nutrition states often include measurements of different acylcarnitines. This has resulted in increased interest regarding the consequences of increased/decreased levels of plasma acylcarnitine concentrations and the mechanisms associated with these changes. Altered acylcarnitine metabolome is characteristic of certain inborn errors of fatty acid metabolism, as well as cardiovascular, metabolic, and neurological diseases in addition to some forms of cancer. Long-chain acylcarnitines accumulate under conditions of insufficient mitochondrial functionality reaching tissue levels that can affect enzyme and ion channel activities, and impact energy metabolism pathways and cellular homeostasis. | ||
A better understanding of biochemical and molecular mechanisms behind the changes in acylcarnitine levels and their physiological and pathological roles forms the basis for future therapeutic target selection and preclinical drug discovery, as well as explains off-target effects of some clinically used drugs. | A better understanding of biochemical and molecular mechanisms behind the changes in acylcarnitine levels and their physiological and pathological roles forms the basis for future therapeutic target selection and preclinical drug discovery, as well as explains off-target effects of some clinically used drugs. | ||
|keywords=acylcarnitine, mitochondrial physiology, energy metabolism, biomarkers, cardiometabolic diseases | |keywords=acylcarnitine, mitochondrial physiology, energy metabolism, biomarkers, cardiometabolic diseases | ||
|editor=Tindle-Solomon L | |editor=Tindle-Solomon L | ||
|mipnetlab=AT Innsbruck Oroboros, LV Riga Liepins E | |mipnetlab=AT Innsbruck Oroboros, LV Riga Liepins E | ||
}} | }} | ||
ORC'''ID''':[[File:ORCID.png|20px|link=https://orcid.org/0000-0002-1739-0928]] Dambrova Maija, [[File:ORCID.png|20px|link=https://orcid.org/0000-0001-7068-6165]] Cecatto Cristiane, [[File:ORCID.png|20px|link=https://orcid.org/0000-0001-9174-4985]] Vilskersts Reinis, [[File:ORCID.png|20px|link=https://orcid.org/0000-0003-2213-8337]] Liepinsh Edgars | ORC'''ID''':[[File:ORCID.png|20px|link=https://orcid.org/0000-0002-1739-0928]] Dambrova Maija, [[File:ORCID.png|20px|link=https://orcid.org/0000-0001-7068-6165]] Cecatto Cristiane, [[File:ORCID.png|20px|link=https://orcid.org/0000-0001-9174-4985]] Vilskersts Reinis, [[File:ORCID.png|20px|link=https://orcid.org/0000-0003-2213-8337]] Liepinsh Edgars | ||
== Support == | == Support == | ||
| Line 38: | Line 27: | ||
|area=Exercise physiology;nutrition;life style, Pharmacology;toxicology | |area=Exercise physiology;nutrition;life style, Pharmacology;toxicology | ||
|preparations= | |preparations= | ||
|enzymes= | |enzymes= | ||
|topics= | |topics= | ||
Revision as of 17:08, 22 May 2022
Dambrova 2022 MitoFit
| Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. MitoFit Preprints 2022.20. https://doi.org/10.26124/mitofit:2022-0020 |
»
Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets
Dambrova Maija, Cecatto Cristiane, Vilskersts Reinis, Liepinsh Edgars (2022-05-20) MitoFit Prep
Abstract:
Acylcarnitines are esters of L-carnitine that emerge from the fatty acid metabolism pathways in mitochondria and peroxisomes.
Metabolomic profiling assays that investigate disease and nutrition states often include measurements of different acylcarnitines. This has resulted in increased interest regarding the consequences of increased/decreased levels of plasma acylcarnitine concentrations and the mechanisms associated with these changes. Altered acylcarnitine metabolome is characteristic of certain inborn errors of fatty acid metabolism, as well as cardiovascular, metabolic, and neurological diseases in addition to some forms of cancer. Long-chain acylcarnitines accumulate under conditions of insufficient mitochondrial functionality reaching tissue levels that can affect enzyme and ion channel activities, and impact energy metabolism pathways and cellular homeostasis.
A better understanding of biochemical and molecular mechanisms behind the changes in acylcarnitine levels and their physiological and pathological roles forms the basis for future therapeutic target selection and preclinical drug discovery, as well as explains off-target effects of some clinically used drugs. • Keywords: acylcarnitine, mitochondrial physiology, energy metabolism, biomarkers, cardiometabolic diseases • Bioblast editor: Tindle-Solomon L • O2k-Network Lab: AT Innsbruck Oroboros, LV Riga Liepins E
ORCID:
Dambrova Maija, Cecatto Cristiane, Vilskersts Reinis, Liepinsh Edgars
Support
- This work was part of the FAT4BRAIN project, with funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement nº 857394..
Labels: MiParea: Exercise physiology;nutrition;life style, Pharmacology;toxicology
Bioblast 2022, FAT4BRAIN
